A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 754 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle... May 27, 2026 Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... March 26, 2025 Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient December 16, 2019 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 Load more HOT NEWS Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... Some People with Rectal Cancer Can Skip Radiation Before Surgery First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR...
